Stemline Therapeutics (STML) Receiving Somewhat Positive Media Coverage, Report Shows

Media coverage about Stemline Therapeutics (NASDAQ:STML) has been trending somewhat positive on Sunday, Accern reports. The research firm identifies negative and positive media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Stemline Therapeutics earned a news sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 46.1446068564503 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Here are some of the media stories that may have effected Accern’s rankings:

Shares of Stemline Therapeutics (NASDAQ STML) opened at $13.90 on Friday. Stemline Therapeutics has a 12-month low of $5.50 and a 12-month high of $16.00. The firm has a market capitalization of $357.93, a P/E ratio of -5.41 and a beta of -0.02.

A number of equities research analysts have issued reports on the company. HC Wainwright set a $38.00 target price on Stemline Therapeutics and gave the stock a “buy” rating in a research report on Thursday, December 14th. BidaskClub cut Stemline Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, December 7th. Finally, Cowen reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research report on Tuesday, October 31st. Three research analysts have rated the stock with a sell rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $33.75.

In other news, COO Kenneth Hoberman sold 11,983 shares of the stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $14.18, for a total value of $169,918.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.70% of the stock is currently owned by corporate insiders.

WARNING: “Stemline Therapeutics (STML) Receiving Somewhat Positive Media Coverage, Report Shows” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Insider Buying and Selling by Quarter for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit